Previous 10 | Next 10 |
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
BeiGene ( NASDAQ: BGNE ) and Novartis ( NYSE: NVS ) said tislelizumab plus chemotherapy helped improve overall (OS) survival in certain patients with esophageal cancer in a late-stage study. Data from the phase 3 trial, dubbed RATIONALE 306, showed tislelizu...
PD-1 inhibitor tislelizumab plus chemotherapy demonstrated a statistically significant and clinically meaningful survival benefit, extending survival by more than six months compared to chemotherapy alone Incidence of most common treatment-related adverse events similar for ...
China is cutting its quarantine time for international travelers to 10 days, which is lending support to sectors like casino stocks. Morgan Stanley just published its Global Exposure Guide, which tracks revenue and cost exposure by region. "While China is a very important source of revenue fo...
TAL Education Group (NYSE:TAL) and Mercury Fintech (NASDAQ:MFH) were added to a list of companies that face possible delisting from U.S. exchanges, the Securities and Exchange Commission said on Friday. The two companies were added to the Holding Foreign Companies Accountable Act, or HF...
BeiGene 's (NASDAQ: BGNE) shares were up by more than 13% on Tuesday at 2:50 p.m. ET thanks to a regulatory body in China accepting one of the company's supplemental biologics licensing application filings for a new indication for its drug tislelizumab. The Center for Drug Evalu...
The ADRs of BeiGene (NASDAQ:BGNE) gained 12% in the pre-market Tuesday after the biotech announced that regulators in China have accepted a marketing application for drug combination involving its anti-PD-1 inhibitor, tislelizumab. With the supplemental biologics license application (sBL...
Submission seeks marketing authorization for use with chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma whose tumor expresses PD-L1 BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-dr...
The U.S. FDA has extended the action date by three months to Jan. 20, 2023 Beigene's (NASDAQ:BGNE) supplemental New Drug Application for Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma. Shares are down 9%. The extension is to review additional ...
BeiGene and NewBridge Pharmaceuticals To Bring BRUKINSA to Patients in MENA Region, Following Approval for Previously Treated Mantle Cell Lymphoma in Kuwait, Bahrain and Qatar BRUKINSA has Previously Been Approved by Regulatory Authorities in the U.S., China, the European Unio...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...